PsA T2T Statin Trial on Carotid and Coronary Atherosclerosis
Status:
Suspended
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with an increased risk
of myocardial infarction (MI). Using coronary computer tomography angiogram (CCTA), it is
found that a significantly higher prevalence of high-risk coronary plaque (non-calcified
plaque [NCP]), supporting the notion that more aggressive cardiovascular (CV) evaluation
strategy should be considered in these patients.
Carotid ultrasound screening in this population may be a better alternative than traditional
risk score to identify patients at high CV risk as the latter underestimated CV risk.
Previous study from our group have demonstrated that achieving treatment target (minimal
disease activity [MDA]) can prevent progression of carotid atherosclerosis. Nevertheless, 38%
of this Treat to Target (T2T) cohort still had carotid plaque progression.
Project description
it is hypothesized that combination of a T2T stratgy together with high-intensity
rosuvastatin treatment (Group 1: T2T-statin group) is more effective in preventing
progression of coronary and carotid atherosclerosis than T2T stratgy alone (Group 2: T2T-only
group) in high-risk PsA patients with carotid plaque.
The primary outcome is to ascertain the effect of T2T strategy with high-intensity
rosuvastain (Group 1: T2T-statin group) on the change in CIMT over a period of 12 months
compared with T2T strategy alone (Group 2: T2T-only group)